I USE LR in the ED

Completed

• Conditions: Kidney Injury

• Registration Number: NCT03807648
• Lead Sponsor: Intermountain Health Care, Inc.

Brief Summary

To study the difference in mortality and major adverse kidney events during and after treatment in the emergency department with intravenous fluids per standard of care at 30 days before and after the system-wide implementation.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-12-20
• Study First Submitted: 2019-01-03
• Study First Submitted QC: 2019-01-14
• Study First Posted: 2019-01-17
• Primary Completion: 2019-12-31
• Study Completion: 2020-01-31
• Status Verified: 2020-02
• Last Update Submitted: 2020-02-10
• Last Update Posted: 2020-02-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200000

Inclusion Criteria

• Adult patients (≥18 years) receiving a minimum of 1000ml of intravenous fluids starting in the emergency department per standard of care

Exclusion Criteria

• Patients aged ≤17 years
• Previously enrolled patients with >1 ED admission within the 30-day follow-up period

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of participants with major Adverse Kidney Events	within 30 days or at hospital discharge	death from any cause, new renal replacement therapy or persistent renal dysfunction
LR IV Fluids administered	Through study completion (an average of 1 year)	Proportion of LR IV fluids following implementation

Secondary Outcome Measures

Name	Time	Method
Cost	Through study completion (an average of 1 year)	Direct costs of ED care and hospitalization
Rate of hospital admission and readmission	Within 30 days of initial ED encounter

Trial Locations

Locations (1)

Intermountain Medical Center; 🇺🇸 Murray, Utah, United States